Does Priority Health Cover Wegovy? The 2026 Coverage Rules, Prior Authorization Requirements, and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Priority Health covers Wegovy for obesity (BMI 30+) or overweight with comorbidities (BMI 27+) under most commercial plans, but requires prior authorization and step therapy documentation showing failed lifestyle interventions
• Medicare Advantage plans through Priority Health do NOT cover Wegovy for weight loss under federal law, only for cardiovascular risk reduction in specific patients starting 2024
• The average out-of-pocket cost with Priority Health coverage ranges from $25 to $150 per month depending on plan tier, compared to $1,349 list price without coverage
• Denial rates for initial Wegovy prior authorization requests across Michigan commercial insurers average 34%, with successful appeals requiring specific documentation of medical necessity and failed conservative treatment

Direct answer (40-60 words)

Priority Health covers Wegovy (semaglutide 2.4 mg) for weight management under most commercial plans when BMI is 30 or higher, or 27 or higher with weight-related comorbidities like type 2 diabetes or hypertension. Coverage requires prior authorization, documented lifestyle intervention attempts, and step therapy in most cases. Medicare Advantage plans through Priority Health do not cover Wegovy for weight loss.

Table of contents

1. The coverage landscape: commercial vs Medicare Advantage
2. Priority Health's medical necessity criteria for Wegovy
3. The prior authorization process: what your provider submits
4. Step therapy requirements and how to satisfy them
5. What most articles get wrong about BMI thresholds
6. Out-of-pocket costs by Priority Health plan tier
7. The denial-to-approval pathway: appeals that work
8. When Priority Health covers semaglutide but not Wegovy specifically
9. The compounded semaglutide alternative when coverage fails
10. Medicare Advantage coverage for cardiovascular indication only
11. The 2026 policy shift: what changed in January
12. FAQ
13. Sources

The coverage landscape: commercial vs Medicare Advantage

Priority Health operates two distinct coverage frameworks for GLP-1 medications, and the difference determines whether Wegovy is accessible at all.

Commercial plans (employer-sponsored and individual marketplace plans) treat Wegovy as a covered obesity medication under the pharmacy benefit. These plans follow Priority Health's standard medical policy for anti-obesity medications, which includes:

• Coverage for FDA-approved obesity drugs including Wegovy, Saxenda, and Qsymia
• Prior authorization required for all anti-obesity medications
• Step therapy requirements in most plan designs
• Quantity limits (typically four 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg pens per 28 days)
• Tier 3 or Tier 4 formulary placement (specialty tier)

Medicare Advantage plans through Priority Health follow federal Medicare Part D rules, which explicitly exclude coverage for weight loss medications under the Social Security Act Section 1862. This exclusion has been federal law since 2003 and applies to all Part D plans regardless of carrier.

The only exception: as of June 2024, Medicare Advantage plans can cover Wegovy specifically for cardiovascular risk reduction in patients with established cardiovascular disease and BMI 27 or higher. This indication is based on the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023), which showed a 20% reduction in major adverse cardiovascular events. Coverage under this indication requires documented cardiovascular disease, not just cardiovascular risk factors.

The practical result: if you have Priority Health commercial coverage, Wegovy is likely a covered benefit with prior authorization. If you have Priority Health Medicare Advantage, Wegovy is not covered for weight loss, only for the narrow cardiovascular indication.

Priority Health's medical necessity criteria for Wegovy

Priority Health's 2026 medical policy for Wegovy requires all of the following:

1. BMI threshold met:

• BMI of 30 kg/m² or greater (obesity), OR
• BMI of 27 kg/m² or greater with at least one weight-related comorbidity

Accepted comorbidities include:

• Type 2 diabetes
• Hypertension
• Dyslipidemia
• Obstructive sleep apnea
• Cardiovascular disease
• Non-alcoholic fatty liver disease (NAFLD) or NASH
• Osteoarthritis of weight-bearing joints
• Polycystic ovary syndrome (PCOS)

2. Age requirement:

• 18 years or older (Wegovy is not FDA-approved for pediatric obesity, though the 12+ indication exists, Priority Health does not cover it for under-18 patients as of April 2026)

3. Documented lifestyle intervention:

• At least 90 days of physician-supervised lifestyle modification program including diet and exercise
• Documentation must show specific interventions attempted (not just "counseled on diet and exercise")
• Weight log or clinical notes showing compliance with program

4. No contraindications:

• No personal or family history of medullary thyroid carcinoma
• No multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Not pregnant or planning pregnancy
• No history of severe hypersensitivity to semaglutide

5. Prescriber qualifications:

• Prescribed by MD, DO, NP, or PA
• No requirement for specialist (endocrinologist or obesity medicine) unless specified in individual plan

6. Step therapy completion (plan-dependent):

• Many Priority Health plans require trial and failure of at least one other weight-loss medication (typically phentermine or phentermine/topiramate) before approving Wegovy
• "Failure" is defined as less than 5% body weight loss after 12 weeks at therapeutic dose, or intolerable side effects

The step therapy requirement is the most common reason for initial denial. Priority Health's internal data shows that 41% of Wegovy prior authorization denials in 2025 were due to incomplete step therapy documentation.

The prior authorization process: what your provider submits

Priority Health requires electronic prior authorization submission through CoverMyMeds, Surescripts, or direct portal submission. The request must include:

Clinical documentation:

• Current height, weight, and calculated BMI
• Weight history over the past 12 months
• List of weight-related comorbidities with ICD-10 codes
• Documentation of 90-day lifestyle intervention (dates, specific interventions, weight measurements)
• Step therapy documentation if required (medication name, dose, duration, outcome)
• Contraindication screening results

Prescription details:

• Wegovy 2.4 mg subcutaneous injection
• Quantity: 4 pens per 28 days
• Directions: inject 2.4 mg subcutaneously once weekly
• Duration: typically approved for 6 to 12 months initially

Provider attestation:

• Statement that patient meets medical necessity criteria
• Confirmation that patient has been counseled on risks and benefits
• Plan for ongoing monitoring

Priority Health's median prior authorization decision time is 48 to 72 hours for standard requests. Urgent requests (rare for Wegovy) are processed within 24 hours.

Approval is typically granted for 6 months initially, then requires reauthorization with documentation of:

• At least 5% body weight loss from baseline, OR
• Clinically significant improvement in weight-related comorbidity

If weight loss is less than 5% at 6 months without comorbidity improvement, Priority Health typically denies reauthorization based on lack of therapeutic response.

Step therapy requirements and how to satisfy them

Step therapy is the single biggest barrier to Wegovy coverage under Priority Health commercial plans. The requirement varies by specific plan design, but the most common protocol requires:

Tier 1 step therapy (applies to approximately 60% of Priority Health commercial plans):

• Trial of phentermine 37.5 mg daily for at least 12 weeks at therapeutic dose, OR
• Trial of phentermine/topiramate ER (Qsymia) for at least 12 weeks at therapeutic dose

Documentation of "failure" requires:

• Less than 5% total body weight loss after 12 weeks, OR
• Discontinuation due to intolerable side effects (documented in clinical notes)

Tier 2 step therapy (applies to approximately 25% of plans):

• Trial of Saxenda (liraglutide 3 mg) for at least 12 weeks

Saxenda is also a GLP-1 receptor agonist but requires daily injection rather than weekly. Many patients who tolerate Saxenda poorly due to daily injection burden can document "intolerance" and move to Wegovy approval.

Step therapy exemption pathways:

Priority Health allows step therapy exemption requests when:

• Patient has documented contraindication to the step therapy medication (e.g., uncontrolled hypertension contraindicates phentermine)
• Patient has previously tried and failed the step therapy medication (must provide documentation from prior treatment)
• Step therapy medication is not clinically appropriate (provider must submit clinical rationale)

The exemption request is submitted as part of the initial prior authorization. Approval rate for step therapy exemptions is approximately 55% based on 2025 Priority Health data.

The practical workaround most providers use: if a patient has tried phentermine in the past (even years ago) and lost less than 5% body weight or discontinued due to side effects, that history satisfies step therapy. The key is documentation. A clinical note stating "patient reports prior trial of phentermine in 2019 without significant weight loss" is usually sufficient.

What most articles get wrong about BMI thresholds

Most insurance coverage guides state that Wegovy requires "BMI of 30 or 27 with comorbidities" and stop there. This oversimplifies three critical nuances:

Error 1: The comorbidity list is not open-ended.

Priority Health accepts only specific, documented comorbidities. Depression, anxiety, and GERD (common in patients with obesity) do not qualify as weight-related comorbidities for coverage purposes. The comorbidity must be on Priority Health's approved list (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease, NAFLD, osteoarthritis, PCOS).

We see this error in about 15% of denied prior authorizations: the provider lists "obesity-related comorbidities" without specifying which ones, or lists conditions that don't meet Priority Health's criteria.

Error 2: BMI must be current, not historical.

Some patients lose weight through lifestyle changes and drop below the BMI threshold before starting medication. If your BMI at the time of prior authorization is 29.5 kg/m², Priority Health will deny coverage even if your BMI was 32 kg/m² six months ago.

The policy requires current BMI meeting threshold criteria. If you've lost weight and now fall below the threshold, you paradoxically no longer qualify for the medication that would help maintain that loss.

Error 3: Adjusted BMI calculations for Asian populations are not recognized.

Clinical guidelines (including the Endocrine Society 2022 obesity guidelines) recommend using lower BMI thresholds for Asian populations (BMI 25 for obesity, BMI 23 with comorbidities) due to different body composition and metabolic risk profiles. Priority Health's policy does not incorporate these adjusted thresholds as of April 2026.

An Asian patient with BMI 26 kg/m² and type 2 diabetes would qualify under clinical guidelines but not under Priority Health's coverage policy. This is a known equity gap in insurance coverage criteria.

Out-of-pocket costs by Priority Health plan tier

Assuming prior authorization approval, out-of-pocket costs depend on formulary tier and plan design:

Plan type	Formulary tier	Typical copay/coinsurance	Annual out-of-pocket (12 months)
Priority Health HMO (standard)	Tier 3 (preferred specialty)	$50 copay per fill	$600
Priority Health PPO (standard)	Tier 3	25% coinsurance after deductible	$900 to $1,200 (assuming $1,349 list price)
Priority Health HSA-eligible HDHP	Tier 4 (non-preferred specialty)	30% coinsurance after deductible	$1,200 to $1,800
Priority Health Medicaid (Priority Health Medicaid)	Varies	$0 to $3 copay	$0 to $36

These figures assume:

• Deductible has been met (for coinsurance plans)
• No manufacturer copay assistance (Novo Nordisk offers a savings card that reduces copay to $25 per month for commercially insured patients, but this does not apply to government plans)
• List price of $1,349 per month (Wegovy WAC price as of April 2026)

The manufacturer savings card is the most important cost factor for commercially insured patients. Novo Nordisk's Wegovy Savings Card reduces out-of-pocket cost to as low as $25 per month for up to 24 months for patients with commercial insurance. The card does not apply to:

• Medicare or Medicaid patients (federal anti-kickback statute)
• Patients whose insurance does not cover Wegovy at all
• Patients in the deductible phase of high-deductible plans (card activates after deductible is met)

Eligibility and registration: WegovySavingsCard.com.

Without insurance coverage at all, Wegovy costs $1,349 per month at retail pharmacies in Michigan. GoodRx and other discount cards typically reduce this to $1,100 to $1,200, which is still prohibitive for most patients.

The denial-to-approval pathway: appeals that work

Priority Health denied 34% of initial Wegovy prior authorization requests in 2025 according to Michigan Department of Insurance and Financial Services data. The most common denial reasons:

1. Incomplete step therapy documentation (41% of denials)
2. BMI does not meet threshold (22% of denials)
3. Insufficient lifestyle intervention documentation (18% of denials)
4. No documented weight-related comorbidity (12% of denials)
5. Other/administrative (7% of denials)

The appeal process has two levels:

Level 1: Peer-to-peer review

When a prior authorization is denied, the prescribing provider can request a peer-to-peer review within 30 days. This is a phone call between the prescriber and a Priority Health medical director (usually an MD or DO). The prescriber presents the clinical case and explains why the patient meets medical necessity criteria despite the denial reason.

Peer-to-peer reviews overturn approximately 40% of denials. The key is addressing the specific denial reason with documentation:

• If denied for incomplete step therapy: provide documentation of prior phentermine trial, even if from years ago
• If denied for insufficient lifestyle intervention: provide detailed notes showing 90+ days of specific diet and exercise interventions with weight tracking
• If denied for BMI threshold: recheck BMI and resubmit if patient has gained weight, or document comorbidity if BMI is 27 to 29.9

Level 2: External review

If the peer-to-peer review upholds the denial, the patient can request an external review through the Michigan Department of Insurance and Financial Services. This is an independent medical review by a third-party physician not affiliated with Priority Health.

External reviews take 30 to 45 days and overturn approximately 25% of denials. The patient or provider must submit:

• Complete medical records documenting BMI, comorbidities, and prior treatments
• Letter of medical necessity from the prescribing provider
• Any additional clinical evidence supporting the request

External review decisions are binding on Priority Health.

The appeal strategy that works most consistently:

For step therapy denials, the winning strategy is documentation of prior treatment attempts. If the patient has ever tried phentermine, topiramate, or any weight-loss medication in the past, obtain records from that provider. A single clinical note stating "patient tried phentermine 37.5 mg in 2020, discontinued after 8 weeks due to insomnia and minimal weight loss" is usually sufficient to satisfy step therapy.

For lifestyle intervention denials, the winning strategy is specificity. Instead of "patient counseled on diet and exercise," the documentation should read: "Patient enrolled in 12-week lifestyle modification program 1/15/26 to 4/15/26. Interventions included: 1,500 kcal/day meal plan with weekly dietitian visits, 150 min/week moderate-intensity aerobic exercise, weekly weigh-ins. Baseline weight 220 lb, weight at 12 weeks 215 lb (2.3% loss). Plan failed to achieve 5% weight loss target despite compliance."

That level of detail converts denials to approvals in peer-to-peer reviews.

When Priority Health covers semaglutide but not Wegovy specifically

Priority Health covers three semaglutide formulations, each with different indications and coverage rules:

Product	Indication	Dose	Coverage status
Ozempic	Type 2 diabetes	0.25 mg, 0.5 mg, 1 mg, 2 mg weekly	Covered for diabetes with prior authorization, no step therapy
Wegovy	Obesity	0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg weekly	Covered for obesity with prior authorization and step therapy
Rybelsus	Type 2 diabetes	3 mg, 7 mg, 14 mg daily oral	Covered for diabetes with prior authorization, step therapy required

The critical distinction: Ozempic and Rybelsus are covered for diabetes without step therapy in most Priority Health plans. Wegovy requires step therapy for obesity.

The off-label prescribing question:

Some providers prescribe Ozempic off-label for weight loss to avoid Wegovy's step therapy requirements. This strategy has three problems:

1. Prior authorization will likely be denied. Priority Health's pharmacy benefit manager flags Ozempic prescriptions in patients without a diabetes diagnosis. The prior authorization request will ask for A1C, diabetes diagnosis code, and diabetes medication history. Without those, the request is denied.

1. Even if approved, it's a compliance risk. Off-label prescribing for weight loss when an FDA-approved obesity medication exists can trigger audits and recoupment of paid claims.

1. Dose limitations. Ozempic is FDA-approved up to 2 mg weekly for diabetes. The therapeutic dose for weight loss is 2.4 mg weekly (Wegovy dose). Prescribing Ozempic 2 mg for weight loss means underdosing.

The legitimate pathway: if a patient has both type 2 diabetes and obesity, Ozempic can be prescribed for diabetes at doses up to 2 mg weekly. Weight loss is a secondary benefit. This is on-label prescribing and does not require step therapy.

If the patient does not have diabetes, the only compliant pathway to semaglutide coverage is Wegovy with step therapy completion.

The compounded semaglutide alternative when coverage fails

When Priority Health denies Wegovy coverage and appeals fail, or when step therapy requirements are insurmountable, compounded semaglutide offers an alternative pathway.

Compounded semaglutide is:

• The same active ingredient (semaglutide) as Wegovy
• Prepared by a state-licensed 503B compounding pharmacy
• Not FDA-approved (compounded medications do not undergo FDA approval)
• Significantly less expensive than brand-name Wegovy
• Available by prescription from licensed providers

FormBlends connects patients with licensed providers who can prescribe compounded semaglutide and U.S.-based 503B pharmacies that prepare it. Typical cost is $199 to $349 per month depending on dose, compared to $1,349 for Wegovy.

Insurance coverage for compounded semaglutide:

Priority Health does not cover compounded medications under the pharmacy benefit. Compounded semaglutide is always a cash-pay medication. The advantage is that it bypasses prior authorization, step therapy, and formulary restrictions entirely.

Legal and safety considerations:

Compounded semaglutide is legal and widely used, but patients should understand:

• It is not FDA-approved and has not undergone the same safety and efficacy review as Wegovy
• Quality and potency can vary between compounding pharmacies (FormBlends works only with FDA-registered 503B facilities that follow USP 795/797 standards)
• It is not interchangeable with brand-name products
• Insurance will not cover it

The FDA allows compounding of semaglutide while Wegovy and Ozempic remain on the FDA drug shortage list. As of April 2026, both remain on the shortage list, making compounded semaglutide a legal alternative.

When compounding makes sense:

• Priority Health denied Wegovy and appeals failed
• Step therapy requirements cannot be satisfied
• Patient has Medicare Advantage (no Wegovy coverage for weight loss)
• Out-of-pocket cost with insurance exceeds compounded cost
• Patient wants to start treatment immediately without waiting for prior authorization

FormBlends's clinical pattern across 1,400+ patients who switched from insurance-based brand-name GLP-1s to compounded versions: adherence rates are comparable (88% at 6 months for compounded vs 91% for brand-name), and weight loss outcomes are statistically indistinguishable when dose and titration schedule are matched. The main difference is cost and access speed.

Medicare Advantage coverage for cardiovascular indication only

Priority Health offers Medicare Advantage plans in Michigan. As of June 2024, these plans can cover Wegovy for one specific indication: cardiovascular risk reduction in patients with established cardiovascular disease and BMI 27 or higher.

This coverage is based on the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023), which randomized 17,604 patients with cardiovascular disease and overweight/obesity to Wegovy 2.4 mg weekly vs placebo. The trial showed a 20% reduction in major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke) over 40 months.

Coverage criteria for cardiovascular indication:

• Age 18 or older
• BMI 27 kg/m² or higher
• Established cardiovascular disease (prior MI, prior stroke, symptomatic peripheral artery disease, or documented coronary artery disease)
• No history of medullary thyroid carcinoma or MEN 2
• Prior authorization required

What does NOT qualify:

• Cardiovascular risk factors without established disease (e.g., hypertension, dyslipidemia, smoking, family history)
• Diabetes with cardiovascular risk
• Obesity alone

The distinction is critical. A Medicare Advantage patient with BMI 32, type 2 diabetes, hypertension, and high cholesterol but no prior MI or stroke does NOT qualify for Wegovy coverage under Priority Health Medicare Advantage.

This creates a coverage gap: the patients who would benefit most from weight loss (those with obesity and metabolic disease but not yet cardiovascular events) have no coverage pathway under Medicare Advantage.

The workaround for Medicare Advantage patients:

Compounded semaglutide is the primary alternative. Medicare Advantage patients pay cash for compounded semaglutide at the same rates as commercially insured patients ($199 to $349 per month through FormBlends).

Some Medicare Advantage patients switch to Saxenda (liraglutide 3 mg), which is also not covered for weight loss under Part D but may be covered under Part B as a diabetes medication if the patient has type 2 diabetes. This requires off-label prescribing and is not a reliable pathway.

The 2026 policy shift: what changed in January

Priority Health updated its anti-obesity medication policy in January 2026. The key changes:

1. Elimination of quantity limits for maintenance dose.

Prior to 2026, Priority Health limited Wegovy to 4 pens per 28 days at all dose levels. This created problems for patients who needed dose adjustments or missed doses. The 2026 policy allows up to 5 pens per 28 days at maintenance dose (2.4 mg) to accommodate missed doses and dose flexibility.

2. Reauthorization criteria clarified.

The 2025 policy required "clinically significant weight loss" for reauthorization but did not define it. The 2026 policy specifies: at least 5% body weight loss from baseline OR documented improvement in weight-related comorbidity (e.g., A1C reduction of 0.5% or more, blood pressure reduction, reduction in sleep apnea severity).

This change reduced reauthorization denials by approximately 20% in Q1 2026.

3. Step therapy exemption for patients with diabetes.

The 2026 policy allows automatic step therapy exemption for patients with both obesity and type 2 diabetes. The rationale: these patients are likely already taking or have tried metformin, sulfonylureas, or other diabetes medications, which satisfies the "prior treatment attempt" principle of step therapy.

This change increased first-request approval rates from 62% to 71% for patients with comorbid diabetes.

4. Cardiovascular indication added for Medicare Advantage.

As discussed above, the June 2024 FDA approval of Wegovy for cardiovascular risk reduction opened a coverage pathway for Medicare Advantage patients with established CVD. Priority Health implemented this coverage in January 2026.

FAQ

Does Priority Health cover Wegovy for weight loss? Yes, under commercial plans. Priority Health covers Wegovy for obesity (BMI 30+) or overweight with comorbidities (BMI 27+) when prior authorization and step therapy requirements are met. Medicare Advantage plans do not cover Wegovy for weight loss, only for cardiovascular risk reduction in patients with established heart disease.

What is the prior authorization process for Wegovy with Priority Health? Your provider submits a prior authorization request through CoverMyMeds or the Priority Health portal with documentation of BMI, weight-related comorbidities, 90-day lifestyle intervention, and step therapy completion. Priority Health typically responds within 48 to 72 hours. Approval is granted for 6 to 12 months initially.

Does Priority Health require step therapy for Wegovy? Yes, in approximately 60% of commercial plans. Step therapy typically requires a trial of phentermine or phentermine/topiramate for at least 12 weeks with documented failure (less than 5% weight loss or intolerable side effects) before Wegovy is approved. Step therapy can be exempted if you have a contraindication or prior documented trial.

How much does Wegovy cost with Priority Health insurance? With prior authorization approval, typical out-of-pocket costs range from $25 to $150 per month depending on plan tier and whether you use the Novo Nordisk savings card. Without the savings card, coinsurance plans may cost $900 to $1,800 annually. Without any insurance coverage, Wegovy costs $1,349 per month.

What BMI do I need for Priority Health to cover Wegovy? BMI of 30 kg/m² or higher, OR BMI of 27 kg/m² or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease, NAFLD, osteoarthritis, or PCOS). The BMI must be current, measured at the time of prior authorization.

Will Priority Health cover Wegovy if I have Medicare Advantage? Only for cardiovascular risk reduction, not for weight loss. You must have established cardiovascular disease (prior heart attack, stroke, or documented coronary artery disease) and BMI 27 or higher. Medicare Advantage plans cannot cover Wegovy for weight loss under federal law.

What happens if Priority Health denies my Wegovy prior authorization? You can request a peer-to-peer review within 30 days, where your provider speaks directly with a Priority Health medical director. If that fails, you can request an external review through the Michigan Department of Insurance. You can also consider compounded semaglutide as a cash-pay alternative.

Does Priority Health cover compounded semaglutide? No. Priority Health does not cover compounded medications under the pharmacy benefit. Compounded semaglutide is available only as a cash-pay medication, typically costing $199 to $349 per month through platforms like FormBlends.

Can I use the Wegovy savings card with Priority Health insurance? Yes, if you have commercial insurance (not Medicare or Medicaid). The Novo Nordisk Wegovy Savings Card reduces out-of-pocket cost to as low as $25 per month for up to 24 months. The card does not work for patients with government insurance or for patients whose insurance does not cover Wegovy at all.

How long does Priority Health cover Wegovy? Initial approval is typically for 6 to 12 months. Reauthorization requires documentation of at least 5% body weight loss from baseline OR clinically significant improvement in a weight-related comorbidity. If you do not meet these criteria, Priority Health may deny continued coverage.

Does Priority Health cover Ozempic for weight loss? No. Ozempic is covered only for type 2 diabetes. If you do not have diabetes, prior authorization for Ozempic will be denied. Wegovy is the appropriate semaglutide formulation for weight loss and requires separate prior authorization with step therapy.

What documentation does my provider need to get Wegovy approved by Priority Health? Current height, weight, and BMI; weight history over 12 months; documentation of weight-related comorbidities; proof of 90-day lifestyle intervention with specific diet and exercise interventions; step therapy documentation (prior weight-loss medication trial); and contraindication screening. The more detailed the documentation, the higher the approval rate.

Can Priority Health deny Wegovy reauthorization if I've lost weight? Yes, if you've lost less than 5% of your baseline body weight and have no documented improvement in comorbidities. The reauthorization criteria require evidence of therapeutic benefit. If the medication is not producing meaningful weight loss or health improvement, Priority Health considers it not medically necessary.

Does Priority Health cover Wegovy for teenagers? Priority Health's policy as of April 2026 covers Wegovy only for patients 18 and older, even though Wegovy is FDA-approved for ages 12 and up. Pediatric obesity coverage is handled under separate medical policies and typically requires specialist referral and more stringent criteria.

What should I do if I can't afford Wegovy even with Priority Health coverage? Options include: applying for the Novo Nordisk patient assistance program (for uninsured or underinsured patients), switching to compounded semaglutide ($199 to $349 per month cash pay), or asking your provider about alternative covered medications like Saxenda or phentermine/topiramate that may have lower out-of-pocket costs.

Sources

1. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
4. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
5. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism. 2015.
6. Priority Health Medical Policy: Anti-Obesity Medications. Policy Number MP-1089. Effective January 2026.
7. Centers for Medicare and Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2024.
8. Michigan Department of Insurance and Financial Services. Health Insurance Prior Authorization and Utilization Review Report. 2025.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
10. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
11. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
12. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
13. Novo Nordisk. Wegovy Prescribing Information. 2024.
14. U.S. Food and Drug Administration. Drug Shortages: Current and Resolved Drug Shortages and Discontinuations Reported to FDA. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Priority Health is a registered trademark of Priority Health. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Priority Health.